홈 > 시장보고서 > 의약품

시장보고서

상품코드

1283948

세계의 폰빌레브란트병(VWD) 치료제 시장 규모, 시장 점유율, 용도 분석, 지역별 전망, 성장 동향, 주요 기업, 경쟁 전략 및 예측(2023-2031년)

Von Willebrand Disease (VWD) Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2023 To 2031

발행일: 2023년 05월 | 리서치사:

Acute Market Reports | 페이지 정보: 영문 118 Pages | 배송안내 : 1-2일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

Von Wilbrand disease(VWD) 치료제 시장은 2031년까지 5.5% 성장할 것으로 예상됩니다. 세계혈우연맹(WFH)에 따르면, 폰빌레브란트병(VWD)은 출혈성 질환 중 가장 흔한 유형으로, VWD 환자는 혈액 내 폰빌레브란트 인자(VWF)라는 출혈을 억제하는 단백질에 문제가 있습니다. 혈관이 손상되어 출혈이 발생하면 VWF는 혈소판이라는 혈액 내 세포가 서로 맞물려 혈전을 형성해 출혈을 막는 것을 돕습니다. 전문가들에 따르면 세계 인구의 약 1%가 VWD를 앓고 있는 것으로 알려졌지만, 증상이 매우 경미하기 때문에 이 질환에 대해 알고 있는 환자는 극소수에 불과합니다. 조사에 따르면 10 명 중 9 명은 진단을받지 않은 것으로 나타났습니다. 폰빌레브란트병 치료 시장은 폰빌레브란트병의 유형에 따라 1형, 2형, 3형으로 나뉩니다. 폰빌레브란트병에 사용되는 치료법은 데스모프레신(DDAVP), 호르몬 대체요법, 피임약, 항선용해제 또는 혈전 안정제, 섬유소 실란트 등이 있습니다.

최근 Teva와 Eagle Pharmaceuticals의 Bendeka(Bendamustine)가 만성 림프성 백혈병과 B세포 비호지킨림프종에 대해 보다 짧은 시간 내에 소량으로 투여할 수 있는 새로운 제제로 FDA의 승인을 받았습니다. Eagle과 체결한 계약으로 Bendeka에 대한 미국 내 상업화 권리를 가지고 있으며, 2016년 1분기에 본 치료제를 출시할 예정입니다.

폰윌브란트병 성장의 주요 요인은 폰윌브란트병에 대한 사회적 인식이 높아지면서 북미와 유럽에서 진단율이 증가하고 있는 것으로 나타났습니다. 북미는 폰빌레브란트병 치료제의 가장 큰 시장으로 관찰되었으며, 유럽이 그 뒤를 이었습니다. 아시아태평양은 2016년부터 2022년까지 예측 기간 동안 가장 빠른 CAGR로 성장할 것으로 예상됐습니다. 아시아태평양의 폰빌레브란트병 치료제 시장의 성장을 이끄는 주요 요인은 희귀질환에 대한 인식 증가, 의료 인프라 개발, 높은 가처분 소득, 희귀 유전 질환에 대한 새로운 치료법에 대한 정부 지원 등입니다.

시장 현황 : 세계의 폰빌레브란트병(VWD) 치료제 시장
질환별 세계의 폰빌레브란트병(VWD) 치료제 시장, 2022
의약품별 세계의 폰빌레브란트병(VWD) 치료제 시장, 2022
투여 경로별 세계의 폰빌레브란트병(VWD) 치료제 시장, 2022
지역별 세계의 폰빌레브란트병(VWD) 치료제 시장, 2022
매력적인 투자 제안 : 지역별, 2022

제3장 폰빌레브란트병(VWD) 치료제 시장 : 경쟁 분석

주요 벤더의 시장 포지셔닝
벤더가 채택하는 전략
주요 산업 전략
Tier 분석 : 2022 vs. 2031

제4장 폰빌레브란트병(VWD) 치료제 시장 : 매크로 분석과 시장 역학

서론
세계의 폰빌레브란트병(VWD) 치료제 시장가치 2021-2031
시장 역학
- 시장 성장 촉진요인
- 시장 성장 억제요인
- 주요 과제
- 주요 기회
성장 촉진요인과 억제요인의 영향 분석
See-Saw 분석

제5장 폰빌레브란트병(VWD) 치료제 질환별 시장, 2021-2031

시장 개요
성장·매출 분석 : 2022 vs. 2031
시장 세분화
- 1형 폰빌레브란트병
- 2형 폰빌레브란트병
- 3형 폰빌레브란트병
- 후천성 폰빌레브란트병

제6장 폰빌레브란트병(VWD) 치료제 의약품별 시장, 2021-2031

시장 개요
성장·매출 분석 : 2022 vs. 2031
시장 세분화
- Desmopressin
- 혈전 안정화 약물
- 대체 요법
- 피임약
- 기타

제7장 폰빌레브란트병(VWD) 치료제 투여 경로별 시장, 2021-2031

시장 개요
성장·매출 분석 : 2022 vs. 2031
시장 세분화
- 경구
- 주입
- 기타

제8장 북미의 폰빌레브란트병(VWD) 치료제 시장, 2021-2031

시장 개요
폰빌레브란트병(VWD) 치료제 질환별 시장, 2021-2031
폰빌레브란트병(VWD) 치료제 의약품별 시장, 2021-2031
폰빌레브란트병(VWD) 치료제 투여 경로별 시장, 2021-2031
폰빌레브란트병(VWD) 치료제 지역별 시장, 2021-2031
- 북미
  - 미국
  - 캐나다
  - 기타 북미

제9장 영국 및 유럽연합의 폰빌레브란트병(VWD) 치료제 시장, 2021-2031

시장 개요
폰빌레브란트병(VWD) 치료제 질환별 시장, 2021-2031
폰빌레브란트병(VWD) 치료제 의약품별 시장, 2021-2031
폰빌레브란트병(VWD) 치료제 투여 경로별 시장, 2021-2031
폰빌레브란트병(VWD) 치료제 지역별 시장, 2021-2031
- 영국과 유럽연합
  - 영국
  - 독일
  - 스페인
  - 이탈리아
  - 프랑스
  - 기타 유럽

제10장 아시아태평양의 폰빌레브란트병(VWD) 치료제 시장, 2021-2031

시장 개요
폰빌레브란트병(VWD) 치료제 질환별 시장, 2021-2031
폰빌레브란트병(VWD) 치료제 의약품별 시장, 2021-2031
폰빌레브란트병(VWD) 치료제 투여 경로별 시장, 2021-2031
폰빌레브란트병(VWD) 치료제 지역별 시장, 2021-2031
- 아시아태평양
  - 중국
  - 일본
  - 인도
  - 호주
  - 한국
  - 기타 아시아태평양

제11장 라틴아메리카의 폰빌레브란트병(VWD) 치료제 시장, 2021-2031

시장 개요
폰빌레브란트병(VWD) 치료제 질환별 시장, 2021-2031
폰빌레브란트병(VWD) 치료제 의약품별 시장, 2021-2031
폰빌레브란트병(VWD) 치료제 투여 경로별 시장, 2021-2031
폰빌레브란트병(VWD) 치료제 지역별 시장, 2021-2031
- 라틴아메리카
  - 브라질
  - 멕시코
  - 기타 라틴아메리카

제12장 중동 및 아프리카의 폰빌레브란트병(VWD) 치료제 시장, 2021-2031

시장 개요
폰빌레브란트병(VWD) 치료제 질환별 시장, 2021-2031
폰빌레브란트병(VWD) 치료제 의약품별 시장, 2021-2031
폰빌레브란트병(VWD) 치료제 투여 경로별 시장, 2021-2031
폰빌레브란트병(VWD) 치료제 지역별 시장, 2021-2031
- 중동 및 아프리카
  - GCC
  - 아프리카
  - 기타 중동 및 아프리카

제13장 기업 개요

Octapharma AG
Grifols S.A.
Shire plc
Bayer AG
CSL Behring
Pfizer Inc.
Akorn Inc.
Ferring B.V.
기타 주목 기업

LSH 23.06.13

Von Willebrand Disease (VWD) Treatment Market is Expected to Grow at 5.5% by 2031. According to World Federation of Hemophilia (WFH), von Willebrand disease (VWD) is the most common type of bleeding disorder. People with VWD have a problem with a protein in their blood called von Willebrand factor (VWF) that helps control bleeding. When a blood vessel is injured and bleeding occurs, VWF helps cells in the blood, called platelets, mesh together and form a clot to stop the bleeding. According to market experts, around 1% of the world's population suffers from VWD, but due to presence of very mild symptoms only a few number of patients are aware about the condition. Research has shown that as many as 9 out of 10 people with VWD have not been diagnosed. On the basis of type of VWD, von Willebrand disease treatment market can be segmented as Type 1 VWD, Type 2 VWD and Type 3 VWD. The types of therapeutic treatments used against von Willebrand disease are Desmopressin (DDAVP), hormone replacement therapy, contraceptives, anti-fibrinolytic or clot-stabilizing drugs, and fibrin sealants.

Recently, the FDA has approved Bendeka (bendamustine) product of Teva and Eagle Pharmaceuticals, a novel drug formulation that can be administered via a shorter, lower-volume infusion - for chronic lymphocytic leukaemia and B-cell non-Hodgkin's lymphoma.It was observed that Teva received US commercialisation rights to Bendeka under a deal with Eagle signed in February, and plans to launch the therapy during the first quarter of 2016.

The key factor responsible for growth of von Willebrand disease is increasing public awareness related to VWD which is fueling the diagnosis rate in North America and Europe. North America was observed as the largest market for von Willebrand disease treatment followed by Europe. Asia Pacific was anticipated to grow at a fastest CAGR during the forecast period 2016 to 2022. The key factors assisting the growth of Asia Pacific von Willebrand disease treatment market are the rising awareness associated with the rare diseases, developing healthcare infrastructure, high disposable income and government support for novel treatment against rare genetic diseases.

Key Players Identified for von Willebrand disease (VWD) Treatment Market Include but are Not Limited to:

Octapharma AG, Crifols, S.A., Shire plc, Bayer AG, CSL Behring, Pfizer, Inc., Akorn, Inc., Ferring B.V. Other Notable Players.

Historical & Forecast Period

This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2031.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Von Willebrand Disease (VWD) Treatment market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Von Willebrand Disease (VWD) Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Disease Type

Type 1 von Willebrand Disease
Type 2 von Willebrand Disease
Type 3 von Willebrand Disease
Acquired von Willebrand Disease

Drug

Desmopressin
Clot-stabilizing Medications
Replacement Therapies
Contraceptives
Others

Route of Administration

Oral
Injection
Others

Region Segment (2021-2031; US$ Million)

North America
- U.S.
- Canada
- Rest of North America

UK and European Union
- UK
- Germany
- Spain
- Italy
- France
- Rest of Europe

Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific

Latin America
- Brazil
- Mexico
- Rest of Latin America

Middle East and Africa
- GCC
- Africa
- Rest of Middle East and Africa

Key questions answered in this report:

What are the key micro and macro environmental factors that are impacting the growth of Von Willebrand Disease (VWD) Treatment market?

What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2031.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Von Willebrand Disease (VWD) Treatment market?

Which is the largest regional market for Von Willebrand Disease (VWD) Treatment market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Von Willebrand Disease (VWD) Treatment market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Von Willebrand Disease (VWD) Treatment market worldwide?

1. Preface

1.1. Report Description
- 1.1.1. Purpose of the Report
- 1.1.2. Target Audience
- 1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
- 1.3.1. Phase I - Secondary Research
- 1.3.2. Phase II - Primary Research
- 1.3.3. Phase III - Expert Panel Review
- 1.3.4. Assumptions
- 1.3.5. Approach Adopted

2. Executive Summary

2.1. Market Snapshot: Global Von Willebrand Disease (VWD) Treatment Market
2.2. Global Von Willebrand Disease (VWD) Treatment Market, By Disease Type, 2022 (US$ Million)
2.3. Global Von Willebrand Disease (VWD) Treatment Market, By Drug, 2022 (US$ Million)
2.4. Global Von Willebrand Disease (VWD) Treatment Market, By Route of Administration, 2022 (US$ Million)
2.5. Global Von Willebrand Disease (VWD) Treatment Market, By Geography, 2022 (US$ Million)
2.6. Attractive Investment Proposition by Geography, 2022

3. Von Willebrand Disease (VWD) Treatment Market: Competitive Analysis

3.1. Market Positioning of Key Von Willebrand Disease (VWD) Treatment Market Vendors
3.2. Strategies Adopted by Von Willebrand Disease (VWD) Treatment Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2022 Versus 2031

4. Von Willebrand Disease (VWD) Treatment Market: Macro Analysis & Market Dynamics

4.1. Introduction
4.2. Global Von Willebrand Disease (VWD) Treatment Market Value, 2021 - 2031, (US$ Million)
4.3. Market Dynamics
- 4.3.1. Market Drivers
- 4.3.2. Market Restraints
- 4.3.3. Key Challenges
- 4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis

5. Von Willebrand Disease (VWD) Treatment Market: By Disease Type, 2021-2031, USD (Million)

5.1. Market Overview
5.2. Growth & Revenue Analysis: 2022 Versus 2031
5.3. Market Segmentation
- 5.3.1. Type 1 von Willebrand Disease
- 5.3.2. Type 2 von Willebrand Disease
- 5.3.3. Type 3 von Willebrand Disease
- 5.3.4. Acquired von Willebrand Disease

6. Von Willebrand Disease (VWD) Treatment Market: By Drug, 2021-2031, USD (Million)

6.1. Market Overview
6.2. Growth & Revenue Analysis: 2022 Versus 2031
6.3. Market Segmentation
- 6.3.1. Desmopressin
- 6.3.2. Clot-stabilizing Medications
- 6.3.3. Replacement Therapies
- 6.3.4. Contraceptives
- 6.3.5. Others

7. Von Willebrand Disease (VWD) Treatment Market: By Route of Administration, 2021-2031, USD (Million)

7.1. Market Overview
7.2. Growth & Revenue Analysis: 2022 Versus 2031
7.3. Market Segmentation
- 7.3.1. Oral
- 7.3.2. Injection
- 7.3.3. Others

8. North America Von Willebrand Disease (VWD) Treatment Market, 2021-2031, USD (Million)

8.1. Market Overview
8.2. Von Willebrand Disease (VWD) Treatment Market: By Disease Type, 2021-2031, USD (Million)
8.3. Von Willebrand Disease (VWD) Treatment Market: By Drug, 2021-2031, USD (Million)
8.4. Von Willebrand Disease (VWD) Treatment Market: By Route of Administration, 2021-2031, USD (Million)
8.5.Von Willebrand Disease (VWD) Treatment Market: By Region, 2021-2031, USD (Million)
- 8.5.1.North America
  - 8.5.1.1. U.S.
    - 8.5.1.1.1. Von Willebrand Disease (VWD) Treatment Market: By Disease Type, 2021-2031, USD (Million)
    - 8.5.1.1.1. Von Willebrand Disease (VWD) Treatment Market: By Drug, 2021-2031, USD (Million)
    - 8.5.1.1.1. Von Willebrand Disease (VWD) Treatment Market: By Route of Administration, 2021-2031, USD (Million)
  - 8.5.1.2. Canada
    - 8.5.1.2.1. Von Willebrand Disease (VWD) Treatment Market: By Disease Type, 2021-2031, USD (Million)
    - 8.5.1.2.1. Von Willebrand Disease (VWD) Treatment Market: By Drug, 2021-2031, USD (Million)
    - 8.5.1.2.1. Von Willebrand Disease (VWD) Treatment Market: By Route of Administration, 2021-2031, USD (Million)
  - 8.5.1.3. Rest of North America
    - 8.5.1.3.1. Von Willebrand Disease (VWD) Treatment Market: By Disease Type, 2021-2031, USD (Million)
    - 8.5.1.3.1. Von Willebrand Disease (VWD) Treatment Market: By Drug, 2021-2031, USD (Million)
    - 8.5.1.3.1. Von Willebrand Disease (VWD) Treatment Market: By Route of Administration, 2021-2031, USD (Million)

9. UK and European Union Von Willebrand Disease (VWD) Treatment Market, 2021-2031, USD (Million)

9.1. Market Overview
9.2. Von Willebrand Disease (VWD) Treatment Market: By Disease Type, 2021-2031, USD (Million)
9.3. Von Willebrand Disease (VWD) Treatment Market: By Drug, 2021-2031, USD (Million)
9.4. Von Willebrand Disease (VWD) Treatment Market: By Route of Administration, 2021-2031, USD (Million)
9.5.Von Willebrand Disease (VWD) Treatment Market: By Region, 2021-2031, USD (Million)
- 9.5.1.UK and European Union
  - 9.5.1.1. UK
    - 9.5.1.1.1. Von Willebrand Disease (VWD) Treatment Market: By Disease Type, 2021-2031, USD (Million)
    - 9.5.1.1.1. Von Willebrand Disease (VWD) Treatment Market: By Drug, 2021-2031, USD (Million)
    - 9.5.1.1.1. Von Willebrand Disease (VWD) Treatment Market: By Route of Administration, 2021-2031, USD (Million)
  - 9.5.1.2. Germany
    - 9.5.1.2.1. Von Willebrand Disease (VWD) Treatment Market: By Disease Type, 2021-2031, USD (Million)
    - 9.5.1.2.1. Von Willebrand Disease (VWD) Treatment Market: By Drug, 2021-2031, USD (Million)
    - 9.5.1.2.1. Von Willebrand Disease (VWD) Treatment Market: By Route of Administration, 2021-2031, USD (Million)
  - 9.5.1.3. Spain
    - 9.5.1.3.1. Von Willebrand Disease (VWD) Treatment Market: By Disease Type, 2021-2031, USD (Million)
    - 9.5.1.3.1. Von Willebrand Disease (VWD) Treatment Market: By Drug, 2021-2031, USD (Million)
    - 9.5.1.3.1. Von Willebrand Disease (VWD) Treatment Market: By Route of Administration, 2021-2031, USD (Million)
  - 9.5.1.4. Italy
    - 9.5.1.4.1. Von Willebrand Disease (VWD) Treatment Market: By Disease Type, 2021-2031, USD (Million)
    - 9.5.1.4.1. Von Willebrand Disease (VWD) Treatment Market: By Drug, 2021-2031, USD (Million)
    - 9.5.1.4.1. Von Willebrand Disease (VWD) Treatment Market: By Route of Administration, 2021-2031, USD (Million)
  - 9.5.1.5. France
    - 9.5.1.5.1. Von Willebrand Disease (VWD) Treatment Market: By Disease Type, 2021-2031, USD (Million)
    - 9.5.1.5.1. Von Willebrand Disease (VWD) Treatment Market: By Drug, 2021-2031, USD (Million)
    - 9.5.1.5.1. Von Willebrand Disease (VWD) Treatment Market: By Route of Administration, 2021-2031, USD (Million)
  - 9.5.1.6. Rest of Europe
    - 9.5.1.6.1. Von Willebrand Disease (VWD) Treatment Market: By Disease Type, 2021-2031, USD (Million)
    - 9.5.1.6.1. Von Willebrand Disease (VWD) Treatment Market: By Drug, 2021-2031, USD (Million)
    - 9.5.1.6.1. Von Willebrand Disease (VWD) Treatment Market: By Route of Administration, 2021-2031, USD (Million)

10. Asia Pacific Von Willebrand Disease (VWD) Treatment Market, 2021-2031, USD (Million)

10.1. Market Overview
10.2. Von Willebrand Disease (VWD) Treatment Market: By Disease Type, 2021-2031, USD (Million)
10.3. Von Willebrand Disease (VWD) Treatment Market: By Drug, 2021-2031, USD (Million)
10.4. Von Willebrand Disease (VWD) Treatment Market: By Route of Administration, 2021-2031, USD (Million)
10.5.Von Willebrand Disease (VWD) Treatment Market: By Region, 2021-2031, USD (Million)
- 10.5.1.Asia Pacific
  - 10.5.1.1. China
    - 10.5.1.1.1. Von Willebrand Disease (VWD) Treatment Market: By Disease Type, 2021-2031, USD (Million)
    - 10.5.1.1.1. Von Willebrand Disease (VWD) Treatment Market: By Drug, 2021-2031, USD (Million)
    - 10.5.1.1.1. Von Willebrand Disease (VWD) Treatment Market: By Route of Administration, 2021-2031, USD (Million)
  - 10.5.1.2. Japan
    - 10.5.1.2.1. Von Willebrand Disease (VWD) Treatment Market: By Disease Type, 2021-2031, USD (Million)
    - 10.5.1.2.1. Von Willebrand Disease (VWD) Treatment Market: By Drug, 2021-2031, USD (Million)
    - 10.5.1.2.1. Von Willebrand Disease (VWD) Treatment Market: By Route of Administration, 2021-2031, USD (Million)
  - 10.5.1.3. India
    - 10.5.1.3.1. Von Willebrand Disease (VWD) Treatment Market: By Disease Type, 2021-2031, USD (Million)
    - 10.5.1.3.1. Von Willebrand Disease (VWD) Treatment Market: By Drug, 2021-2031, USD (Million)
    - 10.5.1.3.1. Von Willebrand Disease (VWD) Treatment Market: By Route of Administration, 2021-2031, USD (Million)
  - 10.5.1.4. Australia
    - 10.5.1.4.1. Von Willebrand Disease (VWD) Treatment Market: By Disease Type, 2021-2031, USD (Million)
    - 10.5.1.4.1. Von Willebrand Disease (VWD) Treatment Market: By Drug, 2021-2031, USD (Million)
    - 10.5.1.4.1. Von Willebrand Disease (VWD) Treatment Market: By Route of Administration, 2021-2031, USD (Million)
  - 10.5.1.5. South Korea
    - 10.5.1.5.1. Von Willebrand Disease (VWD) Treatment Market: By Disease Type, 2021-2031, USD (Million)
    - 10.5.1.5.1. Von Willebrand Disease (VWD) Treatment Market: By Drug, 2021-2031, USD (Million)
    - 10.5.1.5.1. Von Willebrand Disease (VWD) Treatment Market: By Route of Administration, 2021-2031, USD (Million)
  - 10.5.1.6. Rest of Asia Pacific
    - 10.5.1.6.1. Von Willebrand Disease (VWD) Treatment Market: By Disease Type, 2021-2031, USD (Million)
    - 10.5.1.6.1. Von Willebrand Disease (VWD) Treatment Market: By Drug, 2021-2031, USD (Million)
    - 10.5.1.6.1. Von Willebrand Disease (VWD) Treatment Market: By Route of Administration, 2021-2031, USD (Million)

11. Latin America Von Willebrand Disease (VWD) Treatment Market, 2021-2031, USD (Million)

11.1. Market Overview
11.2. Von Willebrand Disease (VWD) Treatment Market: By Disease Type, 2021-2031, USD (Million)
11.3. Von Willebrand Disease (VWD) Treatment Market: By Drug, 2021-2031, USD (Million)
11.4. Von Willebrand Disease (VWD) Treatment Market: By Route of Administration, 2021-2031, USD (Million)
11.5.Von Willebrand Disease (VWD) Treatment Market: By Region, 2021-2031, USD (Million)
- 11.5.1.Latin America
  - 11.5.1.1. Brazil
    - 11.5.1.1.1. Von Willebrand Disease (VWD) Treatment Market: By Disease Type, 2021-2031, USD (Million)
    - 11.5.1.1.1. Von Willebrand Disease (VWD) Treatment Market: By Drug, 2021-2031, USD (Million)
    - 11.5.1.1.1. Von Willebrand Disease (VWD) Treatment Market: By Route of Administration, 2021-2031, USD (Million)
  - 11.5.1.2. Mexico
    - 11.5.1.2.1. Von Willebrand Disease (VWD) Treatment Market: By Disease Type, 2021-2031, USD (Million)
    - 11.5.1.2.1. Von Willebrand Disease (VWD) Treatment Market: By Drug, 2021-2031, USD (Million)
    - 11.5.1.2.1. Von Willebrand Disease (VWD) Treatment Market: By Route of Administration, 2021-2031, USD (Million)
  - 11.5.1.3. Rest of Latin America
    - 11.5.1.3.1. Von Willebrand Disease (VWD) Treatment Market: By Disease Type, 2021-2031, USD (Million)
    - 11.5.1.3.1. Von Willebrand Disease (VWD) Treatment Market: By Drug, 2021-2031, USD (Million)
    - 11.5.1.3.1. Von Willebrand Disease (VWD) Treatment Market: By Route of Administration, 2021-2031, USD (Million)

12. Middle East and Africa Von Willebrand Disease (VWD) Treatment Market, 2021-2031, USD (Million)

12.1. Market Overview
12.2. Von Willebrand Disease (VWD) Treatment Market: By Disease Type, 2021-2031, USD (Million)
12.3. Von Willebrand Disease (VWD) Treatment Market: By Drug, 2021-2031, USD (Million)
12.4. Von Willebrand Disease (VWD) Treatment Market: By Route of Administration, 2021-2031, USD (Million)
12.5.Von Willebrand Disease (VWD) Treatment Market: By Region, 2021-2031, USD (Million)
- 12.5.1.Middle East and Africa
  - 12.5.1.1. GCC
    - 12.5.1.1.1. Von Willebrand Disease (VWD) Treatment Market: By Disease Type, 2021-2031, USD (Million)
    - 12.5.1.1.1. Von Willebrand Disease (VWD) Treatment Market: By Drug, 2021-2031, USD (Million)
    - 12.5.1.1.1. Von Willebrand Disease (VWD) Treatment Market: By Route of Administration, 2021-2031, USD (Million)
  - 12.5.1.2. Africa
    - 12.5.1.2.1. Von Willebrand Disease (VWD) Treatment Market: By Disease Type, 2021-2031, USD (Million)
    - 12.5.1.2.1. Von Willebrand Disease (VWD) Treatment Market: By Drug, 2021-2031, USD (Million)
    - 12.5.1.2.1. Von Willebrand Disease (VWD) Treatment Market: By Route of Administration, 2021-2031, USD (Million)
  - 12.5.1.3. Rest of Middle East and Africa
    - 12.5.1.3.1. Von Willebrand Disease (VWD) Treatment Market: By Disease Type, 2021-2031, USD (Million)
    - 12.5.1.3.1. Von Willebrand Disease (VWD) Treatment Market: By Drug, 2021-2031, USD (Million)
    - 12.5.1.3.1. Von Willebrand Disease (VWD) Treatment Market: By Route of Administration, 2021-2031, USD (Million)

13. Company Profile

13.1. Octapharma AG
- 13.1.1. Company Overview
- 13.1.2. Financial Performance
- 13.1.3. Product Portfolio
- 13.1.4. Strategic Initiatives
13.2. Grifols, S.A.
- 13.2.1. Company Overview
- 13.2.2. Financial Performance
- 13.2.3. Product Portfolio
- 13.2.4. Strategic Initiatives
13.3. Shire plc
- 13.3.1. Company Overview
- 13.3.2. Financial Performance
- 13.3.3. Product Portfolio
- 13.3.4. Strategic Initiatives
13.4. Bayer AG
- 13.4.1. Company Overview
- 13.4.2. Financial Performance
- 13.4.3. Product Portfolio
- 13.4.4. Strategic Initiatives
13.5. CSL Behring
- 13.5.1. Company Overview
- 13.5.2. Financial Performance
- 13.5.3. Product Portfolio
- 13.5.4. Strategic Initiatives
13.6. Pfizer, Inc.
- 13.6.1. Company Overview
- 13.6.2. Financial Performance
- 13.6.3. Product Portfolio
- 13.6.4. Strategic Initiatives
13.7. Akorn, Inc.
- 13.7.1. Company Overview
- 13.7.2. Financial Performance
- 13.7.3. Product Portfolio
- 13.7.4. Strategic Initiatives
13.8. Ferring B.V.
- 13.8.1. Company Overview
- 13.8.2. Financial Performance
- 13.8.3. Product Portfolio
- 13.8.4. Strategic Initiatives
13.9. Other Notable Players
- 13.9.1. Company Overview
- 13.9.2. Financial Performance
- 13.9.3. Product Portfolio
- 13.9.4. Strategic Initiatives

02-2025-2992
(주말 및 공휴일 제외)

라이선스 / 가격

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,500

￦ 6,385,000

PDF (Multi User License)

PDF 보고서를 동일 사업장에서 10명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,500

￦ 9,224,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 9,000

￦ 12,771,000

※ 부가세 별도